Obesity drug coverage in Medicaid remains limited, with 13 state Medicaid programs covering GLP-1s for obesity treatment under FFS as of January 2026 (Figure 1)
In these cases, shared decision-making with an obstetrician and lactation specialist becomes essential
The analogue, liraglutide, was effective in clinical studies (the LEAD trials [16]) and was subsequently tested in a cardiovascular outcome trial, the LEADER trial [17], as demanded by the FDA for new antidiabetic agents
How it works: Your provider submits a prior authorization request to your insurance company
A retrospective medical database analysis of T2D patients (n = 39,275) treated with exenatide or other glucose-lowering therapies (n = 381,218) indicated that the GLP-1 agonist might reduce in 19% the incidence of MACCE and in 12% cardiovascular hospitalizations [71]
Hormones : Response is affected by thyroid and other hormones